This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

X-linked agammaglobulinaemia [Bruton]X-연관 무감마글로불린혈증[브루톤]

ICD-10: D80.0 | Synonyms: Bruton disease, Bruton's agammaglobulinaemia, XLA, BTK deficiency

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description

X-linked agammaglobulinemia (XLA) was first described in 1952 by the American pediatrician Ogden C. Bruton. In an 8-year-old boy hospitalized for recurrent severe bacterial infections, he found that the immunoglobulin fraction was completely absent on serum protein electrophoresis, and he succeeded in reducing the frequency of infections with gamma globulin injections. This report is regarded as a pioneering achievement that first clinically demonstrated the importance of humoral immunity.

Advances in immunological understanding

In the 1960s-1970s, as the distinction between B lymphocytes and T lymphocytes was established, XLA was shown to be a specific defect in B-cell development. In patients, peripheral blood B cells were almost undetectable, while T-cell function was confirmed to be normal.

Discovery of the BTK gene

In 1993, Tsukada et al. and Vetrie et al. almost simultaneously identified the causative gene of XLA as the BTK (Bruton tyrosine kinase) gene on the long arm of the X chromosome (Xq21.33-Xq22). BTK is a non-receptor tyrosine kinase essential for B-cell receptor signaling, and this discovery is a landmark achievement that first elucidated the molecular mechanism of humoral immune deficiency.

Recognition in Korea

In Korea, XLA diagnosis cases began to be reported from the 1990s with the development of pediatric immunology. It is currently registered as a target of national rare disease management, and development of an early screening program to shorten diagnostic delay is under way.

2. Causes

BTK gene mutations

The only cause of XLA is pathogenic variants of the BTK gene located on the long arm of the X chromosome (Xq21.3-Xq22.2). The BTK gene consists of 19 exons, and more than 1,000 pathogenic variants have been reported to date. Variant types are diverse, including missense variants, nonsense variants, splice site variants, deletions, insertions, and large structural variants.

Function of the BTK protein

BTK (Bruton tyrosine kinase) is a non-receptor tyrosine kinase that plays a key role in the B-cell receptor (BCR) signaling pathway. BTK consists of PH, TH, SH3, SH2, and kinase domains. Upon BCR stimulation it is phosphorylated and activated by Syk, and then activates PLCγ2 to induce calcium signaling. This pathway is essential for B-cell proliferation, differentiation, and survival.

Relationship between mutations and clinical phenotype

The type and location of BTK variants are related to the amount and function of residual BTK protein, but basically a clear correlation between BTK expression level and clinical severity has not yet been fully established. Because clinical phenotype differs even among patients with the same variant, environmental factors and genetic background are also understood to influence the phenotype.

3. Genetics

X-linked recessive inheritance

XLA follows an X-linked recessive mode of inheritance. Therefore it develops only in hemizygous males carrying a pathogenic BTK gene variant, while heterozygous females become carriers and mostly have no clinical symptoms. About 40-50% of male patients are estimated to result from sporadic (de novo) mutations without family history.

Structure of the BTK gene

The BTK gene is located on the long arm of the X chromosome (Xq21.3-Xq22) and consists of 19 exons spanning about 37.5 kb. The encoded BTK protein consists of 659 amino acids. BTK belongs to the Tec family of tyrosine kinases and is expressed in the B-cell lineage, monocytes, and macrophages but not in T cells and NK cells.

Genotype-phenotype correlation

In female carriers, non-random X-chromosome inactivation (skewed X-inactivation) is observed, in which B cells carrying the BTK-mutant X chromosome fail to develop and only B cells carrying the normal X chromosome develop. This can be used to identify female carriers.

4. General epidemiology

Worldwide incidence

XLA is the best-known disease among primary antibody deficiencies, with an incidence of about 1 in 100,000-200,000 male newborns. About several thousand new patients are reported worldwide each year, and no large differences in frequency between races or regions have been reported.

Sex distribution

Owing to the nature of X-linked inheritance, almost all patients are male. In extremely rare cases, onset has been reported in females with a BTK variant accompanied by Turner syndrome or an X-chromosome abnormality, but this is very exceptional.

Status in Korea

Accurate prevalence data are limited in Korea, but according to registration status of the rare disease helpline, XLA patients are steadily being registered. Diagnostic delay (average time to diagnosis 2-5 years) remains a problem, and improved access to newborn immunoglobulin screening and genetic testing is needed.

5. Pathophysiology

Blockade of B-cell development

Normally, B cells develop in the bone marrow through the stages of hematopoietic stem cell (HSC) → common lymphoid progenitor (CLP) → pro-B cell → pre-B cell → immature B cell → mature B cell. BTK is essential especially at the transition from the pro-B cell to the pre-B cell stage. In BTK deficiency, pre-B-cell receptor (pre-BCR) signaling does not occur, so B-cell development is blocked at the pro-B-cell stage.

Consequences of absent immunoglobulins

Because B-cell development is blocked, B cells in peripheral blood are almost absent or markedly reduced (less than 1% of normal), and plasma cells and the germinal center structures of lymph nodes are also lost. As a result, all immunoglobulin classes (IgG, IgA, IgM, IgE, IgD) are markedly reduced or almost undetectable.

Mechanism of recurrent bacterial infections

Because of the specific lack of humoral (antibody-mediated) immunity, defense against encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, etc.) is markedly reduced. Recurrent infections of the lungs, sinuses, ears, joints, and gastrointestinal tract occur. Because T-cell function is normal, resistance to opportunistic infections (fungi, mycobacteria) is maintained.

6. Symptoms

Age of onset

Until 4-6 months of age, maternal IgG transferred across the placenta plays a protective role and no symptoms appear. Symptoms of recurrent infection begin after 6-18 months of age, when maternal antibodies are lost. In some mild cases, diagnosis is made at a later age (2-5 years).

Recurrent bacterial infections

The most characteristic symptom is recurrent infection by encapsulated bacteria. The main infection patterns are recurrent otitis media, sinusitis, pneumonia, septic arthritis, meningitis, and sepsis. They respond to ordinary antibiotic treatment but recur frequently.

Specific infections

Enteroviruses (echovirus, poliovirus, coxsackievirus) infection can cause severe complications involving the central nervous system (chronic meningoencephalitis) or the musculoskeletal system (dermatomyositis-like syndrome). Cases of vaccine-derived virus infection after administration of oral poliovirus vaccine (OPV) have been reported, so live vaccination is contraindicated. Chronic diarrhea caused by Giardia lamblia is also a characteristic infection.

Non-infectious complications

Autoimmune diseases (idiopathic thrombocytopenic purpura, hemolytic anemia, neutropenia), culture-negative non-purulent arthritis, and inflammatory gastrointestinal disease may occur. Growth hormone deficiency has been reported to accompany the disease in some patients.

7. Signs

Physical examination findings

Abnormally small or non-palpable tonsils and lymph nodes are a characteristic finding. Splenomegaly is absent or minimal, and unlike normal children, the tonsils do not enlarge with growth. As a result of recurrent infections, bronchiectasis, sinus thickening, and chronic otitis media are identified.

Laboratory findings

Serum immunoglobulin (IgG, IgA, IgM) levels are all markedly decreased, usually IgG < 2 g/L, with IgA and IgM very low or undetectable. Peripheral blood B cells (CD19+ or CD20+) are markedly decreased or absent (less than 1-2% of normal). T-cell number and function are normal. Autoimmune neutropenia is sometimes found on blood counts.

Imaging findings

Bronchiectasis findings from recurrent pneumonia on chest X-ray and CT. Chronic sinusitis and post-otitis sequelae on head and neck CT. Culture-negative arthritis findings are sometimes observed on joint X-rays.

8. Screening

Criteria for clinical suspicion

XLA should be suspected in a boy under 2 years of age with ① recurrent severe bacterial infections, ② absent or atrophic tonsils/lymph nodes, and ③ family history (early death from infection in the mother's side male relatives, etc.).

Quantitative immunoglobulin testing

Quantification of serum immunoglobulins (IgG, IgA, IgM, IgE) is the most basic screening test. If panhypogammaglobulinemia below the age-specific lower limit of normal is confirmed, further testing is performed. XLA is strongly suspected especially when IgG < 2 g/L and IgA and IgM are extremely low or undetectable.

Flow cytometry and BTK expression testing

The percentage and absolute count of CD19+ B cells in peripheral blood are measured. B cells below 2% strongly suggest XLA. BTK expression testing, which confirms BTK protein expression in monocytes (CD14+ cells) by flow cytometry, is also useful.

Screening status in Korea

In Korea, immunoglobulin quantification and lymphocyte subset analysis are widely performed in boys with recurrent infections. A newborn immunoglobulin screening system has not yet been introduced, but access to genetic testing is improving through the Korean rare disease diagnosis support program.

9. Diagnosis

Diagnostic criteria (ESID/PAGID criteria)

The diagnosis is confirmed in a male aged 2 years or older with ① CD19+ B cells below 2%, ② IgG, IgA, and IgM all below 2 standard deviations of the lower limit of normal, and ③ one or more of the following: pathogenic BTK gene variant, absent BTK mRNA, absent BTK protein, or a maternal cousin/brother who meets the same diagnosis.

BTK gene analysis

Pathogenic variants are identified by analyzing all exons and adjacent intron regions of the BTK gene by Sanger sequencing or next-generation sequencing (NGS). In addition to point variants and small insertions/deletions, exon deletions/duplications are detected by MLPA.

Prenatal and family diagnosis

Carrier testing (BTK gene analysis) is performed in female family members such as the mother and sisters of a confirmed patient. In a carrier pregnant woman, after fetal sex is determined by amniocentesis or CVS, prenatal diagnosis is possible by BTK gene analysis if the fetus is male.

10. Treatment

Immunoglobulin replacement therapy (IgRT)

The standard treatment for XLA is immunoglobulin replacement therapy (IgRT). It is administered as intravenous immunoglobulin (IVIG, 400-600 mg/kg, every 3-4 weeks) or subcutaneous immunoglobulin (SCIG, weekly or every two weeks). The target IgG trough level is generally recommended to be 8 g/L or higher, and 10 g/L or higher is recommended when there are pulmonary complications such as bronchiectasis. IgRT must be maintained for life, and through it the frequency and severity of infections can be markedly reduced.

Antibiotic therapy

When infection occurs, appropriate antibiotic treatment is started early. In patients with bronchiectasis, prophylactic antibiotic therapy and chest physiotherapy (airway clearance) are combined.

Treatment of enterovirus infection

For central nervous system enterovirus infection, intraventricular or intrathecal administration of high-titer immunoglobulin is sometimes attempted. The antiviral agent pleconaril has been used in some cases but is not an officially accepted standard treatment.

Gene therapy

Gene therapy (lentiviral vector, CRISPR/Cas9-based) is being studied at the preclinical and early clinical stages and is expected to become a curative treatment option in the future.

11. Prognosis

Change in prognosis after the introduction of IgRT

Before the introduction of IgRT, most XLA patients died in childhood from complications of recurrent bacterial infections. Patients who now receive regular IgRT survive to adulthood and can maintain a relatively normal quality of life.

Main causes of death and morbidity

Even in treated patients, chronic lung disease (bronchiectasis) may progress, leading to decline in pulmonary function. Central nervous system enterovirus infection can have fatal consequences before diagnosis or when treatment is inadequate. Gastrointestinal disease (inflammatory bowel disease-like lesions, Giardia infection) also lowers quality of life.

Long-term follow-up care

Patients need regular pulmonary function tests, chest CT, monitoring of immunoglobulin levels, and surveillance for autoimmune complications. Management of the transition to adult care (transition of care) is important.

12. Prevention

Genetic counseling

The mother of a confirmed patient is a carrier with about 50% probability, so genetic counseling and carrier testing within the family are essential. Female carriers should be given sufficient information about prenatal genetic diagnosis options during pregnancy.

Precautions for vaccination

Live vaccines (oral poliovirus vaccine, varicella vaccine, MMR, etc.) are contraindicated in XLA patients. Family members should receive inactivated poliovirus vaccine instead of oral poliovirus vaccine.

Infection prevention

Maintaining an adequate IgG trough level through sufficient IgRT is the key to infection prevention. Early antibiotic treatment when symptoms of infection occur, minimizing infection exposure at school and daycare, and education on hand hygiene are recommended.

13. References

  1. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722-728.
  2. Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279-290.
  3. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226-233.
  4. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.
  5. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85(4):193-202.
  6. Suri D, Rawat A, Singh S. X-linked agammaglobulinemia. Indian J Pediatr. 2016;83(4):331-337.
  7. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.
  8. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-194.
  9. Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221-230.
  10. Ochs HD, Smith CIE, Puck JM. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. 3rd ed. Oxford University Press; 2013.
  11. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709-727.
  12. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96-128.